All News

2018

October

Media Release / Oct 26, 2018

Novartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in psoriatic arthritis

Read More
Digital and data drive decisions
Story / Oct 24, 2018

On being and becoming a data science company

A conversation with Novartis Chief Digital Officer Bertrand Bodson

Read More
Media Release / Oct 23, 2018

Alcon to develop SMART Suite digital health platform for cataract surgery

Read More
Media Release / Oct 23, 2018

Novartis announces Lancet publication of pioneering study in migraine prevention showing efficacy of Aimovig® where other treatments have failed

Read More
Media Release / Oct 22, 2018

Novartis COMBI-AD study of Tafinlar® + Mekinist® continues to demonstrate relapse free survival benefit in patients with BRAF V600-mutant stage III melanoma

Read More
Media Release / Oct 20, 2018

Novartis investigational BYL719 (alpelisib) plus fulvestrant nearly doubles median PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer compared to fulvestrant alone

Read More
Media Release / Oct 19, 2018

Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC

Read More
Media Release / Oct 19, 2018

Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden

Read More
Media Release / Oct 18, 2018

Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms

Read More
Media Release / Oct 18, 2018

Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth

Read More

Pages

Related Links

Annual Report 2017

Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.

Learn More